Polyzystische Lebererkrankung
Die polyzystische Lebererkrankung ist eine chronische Lebererkrankung, die durch multiple Zystenbildung in der Leber gekennzeichnet ist. Selten finden sich auch zysten in anderen Organen.
Leberzysten | |
![]() |
Multiple Leberzysten sind das charakteristische Symptom der polyzystischen Lebererkrankung. |
Gliederung
Referenzen:
1. |
None (1995) Familial exudative vitreoretinopathy. [^] |
2. |
Shastry BS et. al. (1997) Familial exudative vitreoretinopathy: further evidence for genetic heterogeneity. [^] |
3. |
Hey PJ et. al. (1998) Cloning of a novel member of the low-density lipoprotein receptor family. [^] |
4. |
Dong Y et. al. (1998) Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. [^] |
5. |
de Crecchio G et. al. (1998) Autosomal recessive familial exudative vitreoretinopathy: evidence for genetic heterogeneity. [^] |
6. |
Chen D et. al. (1999) Molecular cloning of mouse Lrp7(Lr3) cDNA and chromosomal mapping of orthologous genes in mouse and human. [^] |
7. |
Mao J et. al. (2001) Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. [^] |
8. |
Twells RC et. al. (2001) The sequence and gene characterization of a 400-kb candidate region for IDDM4 on chromosome 11q13. [^] |
9. |
Gong Y et. al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. [^] |
10. |
Little RD et. al. (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. [^] |
11. |
Kato M et. al. (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. [^] |
12. |
Boyden LM et. al. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. [^] |
13. |
Magoori K et. al. (2003) Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. [^] |
14. |
Fujino T et. al. (2003) Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. [^] |
15. |
Van Wesenbeeck L et. al. (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. [^] |
16. |
Twells RC et. al. (2003) Haplotype structure, LD blocks, and uneven recombination within the LRP5 gene. [^] |
17. |
Kondo H et. al. (2003) Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. [^] |
18. |
Mizuguchi T et. al. (2004) LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density. [^] |
19. |
Toomes C et. al. (2004) Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. [^] |
20. |
Ferrari SL et. al. (2004) Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. [^] |
21. |
Jiao X et. al. (2004) Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. [^] |
22. |
Semënov M et. al. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. [^] |
23. |
Qin M et. al. (2005) Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. [^] |
24. |
Ai M et. al. (2005) Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. [^] |
25. |
Clément-Lacroix P et. al. (2005) Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. [^] |
26. |
Guo YF et. al. (2006) Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. [^] |
27. |
Qin M et. al. (2008) Moderate reduction of Norrin signaling activity associated with the causative missense mutations identified in patients with familial exudative vitreoretinopathy. [^] |
28. |
Yadav VK et. al. (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. [^] |
29. |
Narumi S et. al. (2010) Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. [^] |
30. |
Cui Y et. al. (2011) Lrp5 functions in bone to regulate bone mass. [^] |